Bacillus Calmette Guerin Vaccine provides immunity or protection against tuberculosis (TB). The vaccine may be given to persons at high risk of developing TB.
Due to the COVID-19 pandemic, the global Bacillus Calmette Guerin Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Bacillus Calmette Guerin Vaccine market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Bacillus Calmette Guerin Vaccine landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Immune Type accounting for % of the Bacillus Calmette Guerin Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Bacillus Calmette Guerin Vaccine include Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, AJ Vaccines, Serum Institute of India, Intervax, GSBPL and Statens Serum Institute, etc. In terms of revenue, the global 3 largest players have a % market share of Bacillus Calmette Guerin Vaccine in 2021.
This report focuses on Bacillus Calmette Guerin Vaccine volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Bacillus Calmette Guerin Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Bacillus Calmette Guerin Vaccine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Immune Type
Therapy Type
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
AJ Vaccines
Serum Institute of India
Intervax
GSBPL
Statens Serum Institute
Biomed Lublin
ANLIS Malbran
Fundação Ataulpho de Paiva
BB-NCIPD
Taj Pharmaceuticals
Bio Farma
Microgen
Torlakinstitut
Institut Pasteur de Tunis
IVAC